Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Standard Biotools Inc.

NASDAQ: LAB · Life Sciences · 6 alerts · CIK 1162194

Share price
$0.6210Close, Nov 16
Market cap
$245M
Shares outstanding
394.79MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Standard Biotools Inc. filings on SEC EDGAR ↗

4:37 PM ET 8-K
M&A Deal

Standard Biotools M&A Deal with Treeline Biosciences, Inc.

Standard BioTools Inc. provided a status update regarding its pending acquisition of Treeline Biosciences, Inc., specifically addressing stockholder litigation and demand letters. To avoid potential business delays and moot disclosure claims, the company issued supplemental disclosures to its definitive proxy statement ahead of the special meeting of stockholders scheduled for November 19, 2026.

Counterparty
Treeline Biosciences, Inc.
8:23 AM ET 8-K
Divestiture

Standard Biotools Divestiture to Archimed

Standard BioTools Inc. completed the sale of its Microfluidics business to healthcare investment firm ARCHIMED. The divested business will now operate as a standalone independent entity named Biomark Scientific, focusing on high-throughput genomic profiling and microfluidics technology.

Counterparty
ARCHIMED
4:17 PM ET 8-K
Divestiture

Standard Biotools Divestiture to Archimed

Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days and represents a strategic action to streamline the company's portfolio. Financial terms of the divestiture were not disclosed in the filing.

Counterparty
ARCHIMED
5:28 PM ET 8-K
Divestiture

Standard Biotools Divestiture to Element Biosystems, LLC for $5.5M

Standard BioTools terminated its previous agreement with Multiplex Bio and entered into a new definitive agreement to sell its mass cytometry business to Element Biosystems for $5.5 million in cash. The board determined the unsolicited offer from GMT Venture was a superior proposal, as it provides higher cash proceeds and eliminates a previously required $10 million working capital loan. The divestiture is expected to close by the end of 2026, concurrently with the company's pending merger with Treeline Biosciences.

Value
$5.5M
Counterparty
Element Biosystems, LLC (subsidiary of GMT Venture Partners, LLC)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.